Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

Effect of Listening to Surah Al-Inshirah (The Opening-Up of the Heart) After Cesarean Birth on Postpartum Outcomes

NCT07354334 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-01-01
Last updated
2026-03-05

Condition(s) studied

Postpartum DepressionMaternal-Fetal RelationsSpirituality

Investigational drug(s) / intervention(s)

Listening to Surah Al-Inshirah

Listening to Surah Al-Inshirah: Participants will listen to a standardized audio recording of Surah Al-Inshirah in a quiet and comfortable environment during the first 48 hours after cesarean birth, in addition to routine postpartum care.

Study summary

This randomized controlled trial aims to evaluate the effect of listening to the recitation of Surah Al-Inshirah during the early postpartum period after cesarean birth on women's spiritual well-being, depression levels, and maternal attachment. The postpartum period is a sensitive phase characterized by physical recovery, emotional changes, and adaptation to the maternal role, particularly following cesarean delivery. Spiritual and religious practices are commonly used as coping strategies in this period, especially in Muslim populations.

In this study, women who have undergone cesarean birth will be randomly assigned to either an intervention group or a control group. The intervention group will listen to the recitation of Surah Al-Inshirah in addition to receiving routine postpartum care, while the control group will receive routine postpartum care only. Outcomes related to spiritual well-being, postpartum depression, and maternal attachment will be assessed within the first 48 hours after birth. The findings of this study are expected to contribute to evidence-based, culturally sensitive, and low-cost supportive care practices in the early postpartum period.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Being literate * Able to speak and understand Turkish * Aged 18 years or older * Primiparous women * Having undergone cesarean birth * Gestational age at birth between 37 and 42 weeks * Identifying as Muslim * Willing to participate voluntarily after providing written informed consent * Women who have given birth within the last 48 hours and are hospitalized during the early postpartum period Exclusion Criteria: * Having a diagnosed psychiatric disorder * Newborn admitted to the neonatal intensive care unit * Experiencing stillbirth * Having a hearing impairment Criteria for Withdrawal From the Study * Development of obstetric complications for any reason during the study * Requesting to withdraw from the study during the data collection process * Reporting feeling unwell or uncomfortable during the data collection process

Primary outcome measure(s)

  • Postpartum Depression Level — Within the first 48 hours postpartum
    Postpartum depression will be assessed using the Edinburgh Postnatal Depression Scale (EPDS), a validated self-report questionnaire measuring depressive symptoms in the postpartum period. Higher scores indicate higher levels of depressive symptoms. The EPDS is a validated 10-item self-report questionnaire assessing depressive symptoms in the postpartum period. Each item is scored on a 4-point scale (0-3). Total scores range from 0 to 30, with higher scores indicating more severe depressive symptoms.

Trial sites (1)

FacilityCityRegionStatus
Selçuk University Konya Selçuklu
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07354334 on ClinicalTrials.gov ↗ ← All trials in Turkey